If you've been watching healthcare stocks lately and wondering what's going on, here's the short version: artificial intelligence is about to do to drug development what it did to software engineering. Which is to say, make it faster, cheaper, and frankly a lot more interesting.
The Healthcare Select Sector SPDR Fund (XLV) is having its third-best month against the S&P 500 since 1999. That's not just a good month—that's historic. And a huge chunk of that momentum traces back to one company making very aggressive moves into AI: Eli Lilly & Co. (LLY).
Sure, Lilly's weight-loss drug Zepbound has been wildly popular. But the real story right now is what the company is betting on behind the scenes: using artificial intelligence to completely reimagine how drugs are discovered, designed, and brought to market.
According to Jordi Visser, head of AI Macro Nexus Research at 22V Research, we might be witnessing one of the most significant disruptions in biotech history—something that could rival what semiconductors did for computing.
Building the AI Drug Discovery Machine
Earlier this month, Eli Lilly (LLY) signed a deal worth more than $100 million with Insilico Medicine, a company that uses generative AI to design new drugs entirely on computers. No test tubes required—at least not at first.
This happened just weeks after Lilly partnered with Nvidia Corp. (NVDA) to build what it's calling the most powerful AI supercomputer in the pharmaceutical industry. The goal is simple but audacious: shrink drug development timelines from ten years down to two or three.
"This is the inflection point people need to pay attention to," Visser said in his latest YouTube video. "AI drug discovery means shrinking cost, shrinking time, and increasing efficacy. That means changing profit margins—and ultimately, lower drug prices."
What's quietly taking shape is something Visser calls the "AI Pharma Stack"—a layered system where different companies handle different parts of the process. Alphabet Inc. (GOOGL)'s Isomorphic Labs acts as the brain, using generalizable AI models to decode biology at the molecular level. Insilico Medicine serves as the hands, generating novel drug candidates through AI-powered design. And Eli Lilly (LLY) functions as the body, running clinical trials, navigating regulatory hurdles, and bringing the final products to market.
Together, they're building an integrated, end-to-end system for discovering, testing, and delivering the next generation of medicine. And if it works the way early results suggest it might, the economics of the entire pharmaceutical industry are about to change.
From Ten Years to Three—and 90% Cheaper
Traditionally, developing a single drug takes somewhere between 10 and 12 years and costs upward of $2 billion. Most candidates fail. The ones that succeed have to recoup the cost of all the failures. It's a brutal, expensive, and slow process.
But AI-powered platforms can run high-speed simulations and predictive models that mimic biological interactions before any physical experiments begin. That means fewer dead ends, faster cycles, and a much higher success rate. According to Visser's estimates, drug development costs could fall by as much as 90%, and timelines could shrink to just two or three years.
That's not just incremental improvement. That's a structural shift.
Cancer as a Chronic Condition
Now here's where it gets really interesting. Many of these AI-led pharma firms—including Insilico and Isomorphic—are focusing their early efforts on oncology and immunology. These are devastating diseases, incredibly expensive to treat, and importantly, well-modeled with existing data.
With enough data, AI tools can simulate how new drug compounds interact with cancer cells and the immune system, all before a single patient enters a clinical trial. Isomorphic's models are already predicting protein structures with near-experimental accuracy. That means faster development cycles, fewer failed trials, and ultimately, a much greater chance of success.
"We are on the cusp of being able to say that cancer becomes a chronic condition," Visser said. "If you think that's not investable, or you think AI is a bubble, you're missing the point."
Think about that for a second. What if cancer stopped being a death sentence and became something you managed, like diabetes or high blood pressure? The human impact is obvious. But the financial implications are enormous too.
The Re-Rating of Pharma
For years, pharma stocks like Lilly, Novartis AG (NVS), or Merck & Co Inc. (MRK) were considered slow-growth, defensive names. Stable, sure. But not exactly exciting.
That narrative is changing fast. According to Visser, what semiconductors did for productivity in the digital economy, AI could do for healthcare. Companies once thought of as boring are now at the forefront of radical disruption.
"This is what happened to Oracle. This is what happened to IBM. They go from boring companies to AI platforms," Visser said.
The economics align almost too well. Lower R&D costs mean higher profit margins. Higher margins mean more pricing flexibility—which happens to align with political pressure to lower drug costs. Innovation, regulation, and profitability all pointing in the same direction? That's rare.
Healthcare spending could shift from high-cost acute care to manageable chronic conditions. Productivity improves. Fiscal pressure eases. And investors who dismissed pharma as a sleepy sector suddenly have to reconsider.
"The trades that came out of Ozempic were massive," Visser said. "But this is bigger. Much bigger."
If he's right, we're not just watching a rally in healthcare stocks. We're watching the early stages of a transformation that could reshape how we treat disease, how we price medicine, and how we think about the role of technology in healthcare. And it's happening faster than most people realize.
